|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RNF8 |
Gene summary for RNF8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RNF8 | Gene ID | 9025 |
| Gene name | ring finger protein 8 | |
| Gene Alias | hRNF8 | |
| Cytomap | 6p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O76064 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9025 | RNF8 | LZE2T | Human | Esophagus | ESCC | 4.03e-05 | 9.02e-01 | 0.082 |
| 9025 | RNF8 | LZE4T | Human | Esophagus | ESCC | 6.98e-10 | 3.77e-01 | 0.0811 |
| 9025 | RNF8 | LZE7T | Human | Esophagus | ESCC | 1.26e-06 | 3.82e-01 | 0.0667 |
| 9025 | RNF8 | LZE8T | Human | Esophagus | ESCC | 1.23e-03 | 1.04e-01 | 0.067 |
| 9025 | RNF8 | LZE20T | Human | Esophagus | ESCC | 3.03e-07 | 1.76e-01 | 0.0662 |
| 9025 | RNF8 | LZE24T | Human | Esophagus | ESCC | 7.56e-16 | 3.57e-01 | 0.0596 |
| 9025 | RNF8 | LZE6T | Human | Esophagus | ESCC | 7.59e-07 | 3.05e-01 | 0.0845 |
| 9025 | RNF8 | P1T-E | Human | Esophagus | ESCC | 2.24e-06 | 3.18e-01 | 0.0875 |
| 9025 | RNF8 | P2T-E | Human | Esophagus | ESCC | 1.07e-36 | 6.15e-01 | 0.1177 |
| 9025 | RNF8 | P4T-E | Human | Esophagus | ESCC | 1.00e-26 | 6.46e-01 | 0.1323 |
| 9025 | RNF8 | P5T-E | Human | Esophagus | ESCC | 7.10e-14 | 1.98e-01 | 0.1327 |
| 9025 | RNF8 | P8T-E | Human | Esophagus | ESCC | 2.46e-14 | 2.55e-01 | 0.0889 |
| 9025 | RNF8 | P9T-E | Human | Esophagus | ESCC | 1.13e-14 | 2.92e-01 | 0.1131 |
| 9025 | RNF8 | P10T-E | Human | Esophagus | ESCC | 1.34e-16 | 2.07e-01 | 0.116 |
| 9025 | RNF8 | P11T-E | Human | Esophagus | ESCC | 7.43e-14 | 5.10e-01 | 0.1426 |
| 9025 | RNF8 | P12T-E | Human | Esophagus | ESCC | 3.38e-26 | 5.36e-01 | 0.1122 |
| 9025 | RNF8 | P15T-E | Human | Esophagus | ESCC | 1.00e-07 | 2.36e-01 | 0.1149 |
| 9025 | RNF8 | P16T-E | Human | Esophagus | ESCC | 4.14e-12 | 3.06e-01 | 0.1153 |
| 9025 | RNF8 | P17T-E | Human | Esophagus | ESCC | 2.31e-06 | 2.21e-01 | 0.1278 |
| 9025 | RNF8 | P20T-E | Human | Esophagus | ESCC | 1.23e-13 | 1.81e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00022004 | Thyroid | PTC | somatic diversification of immune receptors | 35/5968 | 77/18723 | 8.56e-03 | 3.59e-02 | 35 |
| GO:00164453 | Thyroid | PTC | somatic diversification of immunoglobulins | 31/5968 | 67/18723 | 9.51e-03 | 3.91e-02 | 31 |
| GO:00164473 | Thyroid | PTC | somatic recombination of immunoglobulin gene segments | 27/5968 | 57/18723 | 1.04e-02 | 4.18e-02 | 27 |
| GO:000238113 | Thyroid | PTC | immunoglobulin production involved in immunoglobulin-mediated immune response | 32/5968 | 70/18723 | 1.05e-02 | 4.23e-02 | 32 |
| GO:001657017 | Thyroid | ATC | histone modification | 243/6293 | 463/18723 | 2.23e-17 | 2.27e-15 | 243 |
| GO:0000209110 | Thyroid | ATC | protein polyubiquitination | 134/6293 | 236/18723 | 1.86e-13 | 9.20e-12 | 134 |
| GO:000635421 | Thyroid | ATC | DNA-templated transcription, elongation | 63/6293 | 91/18723 | 3.89e-12 | 1.55e-10 | 63 |
| GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
| GO:200102026 | Thyroid | ATC | regulation of response to DNA damage stimulus | 121/6293 | 219/18723 | 3.22e-11 | 1.08e-09 | 121 |
| GO:0070936110 | Thyroid | ATC | protein K48-linked ubiquitination | 47/6293 | 65/18723 | 1.98e-10 | 5.86e-09 | 47 |
| GO:000636822 | Thyroid | ATC | transcription elongation from RNA polymerase II promoter | 49/6293 | 69/18723 | 2.32e-10 | 6.72e-09 | 49 |
| GO:003278414 | Thyroid | ATC | regulation of DNA-templated transcription, elongation | 39/6293 | 53/18723 | 3.04e-09 | 7.10e-08 | 39 |
| GO:0051054110 | Thyroid | ATC | positive regulation of DNA metabolic process | 107/6293 | 201/18723 | 7.10e-09 | 1.54e-07 | 107 |
| GO:000931426 | Thyroid | ATC | response to radiation | 210/6293 | 456/18723 | 1.69e-08 | 3.39e-07 | 210 |
| GO:0010212110 | Thyroid | ATC | response to ionizing radiation | 82/6293 | 148/18723 | 3.88e-08 | 7.15e-07 | 82 |
| GO:0006325110 | Thyroid | ATC | chromatin organization | 189/6293 | 409/18723 | 6.40e-08 | 1.13e-06 | 189 |
| GO:003424314 | Thyroid | ATC | regulation of transcription elongation from RNA polymerase II promoter | 25/6293 | 32/18723 | 3.13e-07 | 4.68e-06 | 25 |
| GO:200102214 | Thyroid | ATC | positive regulation of response to DNA damage stimulus | 59/6293 | 105/18723 | 1.62e-06 | 1.97e-05 | 59 |
| GO:000628211 | Thyroid | ATC | regulation of DNA repair | 68/6293 | 130/18723 | 8.19e-06 | 8.27e-05 | 68 |
| GO:003424412 | Thyroid | ATC | negative regulation of transcription elongation from RNA polymerase II promoter | 14/6293 | 16/18723 | 1.32e-05 | 1.26e-04 | 14 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RNF8 | SNV | Missense_Mutation | novel | c.544G>A | p.Glu182Lys | p.E182K | O76064 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| RNF8 | SNV | Missense_Mutation | novel | c.575A>G | p.Lys192Arg | p.K192R | O76064 | protein_coding | tolerated(0.41) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RNF8 | SNV | Missense_Mutation | c.1199N>G | p.Glu400Gly | p.E400G | O76064 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RNF8 | SNV | Missense_Mutation | rs149686329 | c.272G>A | p.Arg91His | p.R91H | O76064 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RNF8 | SNV | Missense_Mutation | novel | c.497N>T | p.Ala166Val | p.A166V | O76064 | protein_coding | tolerated(0.07) | benign(0.01) | TCGA-JX-A5QV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RNF8 | SNV | Missense_Mutation | c.849N>T | p.Lys283Asn | p.K283N | O76064 | protein_coding | tolerated(0.11) | benign(0.012) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RNF8 | SNV | Missense_Mutation | novel | c.1076A>C | p.Lys359Thr | p.K359T | O76064 | protein_coding | deleterious(0.02) | benign(0.154) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RNF8 | SNV | Missense_Mutation | c.229N>G | p.Met77Val | p.M77V | O76064 | protein_coding | deleterious(0.03) | benign(0.034) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| RNF8 | SNV | Missense_Mutation | c.370G>A | p.Val124Ile | p.V124I | O76064 | protein_coding | deleterious(0.02) | benign(0.255) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RNF8 | SNV | Missense_Mutation | rs759453955 | c.503N>A | p.Gly168Asp | p.G168D | O76064 | protein_coding | tolerated(0.06) | benign(0.142) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9025 | RNF8 | KINASE, ENZYME | carboplatin | CARBOPLATIN | 30071039 | |
| 9025 | RNF8 | KINASE, ENZYME | docetaxel | DOCETAXEL | 30071039 | |
| 9025 | RNF8 | KINASE, ENZYME | trastuzumab | TRASTUZUMAB | 30071039 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |